巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    MEI Pharma

    MEIP
    0.586
    0.030
    5.59%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・MEI Pharma - 延遲價格・最後更新於 06/07 7:39
    最高位
    0.595
    最低位
    0.553
    開市價
    --
    前收市價
    0.555
    成交量(千)
    39.32
    成交額(百萬)
    0.21
    買入
    0.582
    賣出
    0.586
    每手股數
    --
    市值(百萬)
    77.96
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    3.550 - 0.405
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    MEI Pharma
    證券代碼
    MEIP.US
    所屬板塊
    Biotechnology
    公司業務
    MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
    發行量
    112678498
    公司總部
    11455 El Camino Real, Suite 250
    公司網址
    https://www.meipharma.com
    公司電郵
    investor@meipharma.com
    公司電話
    +1 858 369-7100

    美股異動 | MEI製藥(MEIP.US)跌43.09% FDA要求需要進行隨機實驗才能評估藥物 券商降低評級

    格隆匯·
    美股異動 | MEI製藥(MEIP.US)跌43.09% FDA要求需要進行隨機實驗才能評估藥物 券商降低評級

    美股異動 | MEI製藥(MEIP.US)跌43.09% FDA要求需要進行隨機實驗才能評估藥物 券商降低評級

    格隆匯·
    美股異動 | MEI製藥(MEIP.US)跌43.09% FDA要求需要進行隨機實驗才能評估藥物 券商降低評級

    關於

    MEI Pharma(MEIP.US)所屬的行業板塊為Biotechnology。
    MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
    詳細公司背景可參考: https://www.meipharma.com